Skip to main content

Table 2 Memantine dosing schedule in mg/day by body weight; study period II

From: Glutamatergic medication in the treatment of obsessive compulsive disorder (OCD) and autism spectrum disorder (ASD) – study protocol for a randomised controlled trial

  Dose range (mg/day)a of distributed medication at … (for weeks …):  
Screening/Baseline Weight (kg) V3 (wk 1) V4 (wk 2) V5 (wks 3–4) V6 (wks 5–8) V8 (wks 9–12) b V9 (wk 13) (discontinuation)
≥60 5 10 15 15 15 10 → 5 → 0
40–59 5 10 10 10 10 5 → 0
20–39 5 5 5 5 5 5 → 0
  1. Dose titration aims at target doses as indicated in the table, based on clinical judgment.
  2. aDosage may be adjusted upwards and downwards by 5 mg/day increments within the range shown for each weight group at indicated visits/dates
  3. bDose should remain stable during the last 4 weeks of study period II (weeks 9–12), unless a dose reduction is necessary for tolerability or safety reasons, based on clinical judgment